Cystic fibrosis program characteristics associated with adoption of 2013 infection prevention and control recommendations - 23/08/19

Highlights |
• | Adoption of the 2013 CF infection control guideline was high, but varied by program. |
• | Contact precautions and universal mask use by patients were most commonly adopted. |
• | The “6-foot rule” and auditing disinfection of surfaces were least adopted. |
• | Larger center size was associated with increased adoption. |
Résumé |
Background |
The Cystic Fibrosis (CF) Foundation disseminated an updated guideline for infection prevention and control (IP&C) practices for CF care programs in 2013. Assessing adoption rates of IP&C recommendations is crucial to evaluate their impact.
Methods |
CF care programs provided their written IP&C policies for CF. Policies were analyzed to determine adoption of selected recommendations new in 2013, as well as recommendations made in both 2003 and 2013. Weighted adoption scores were analyzed for association with program characteristics.
Results |
The median number of new recommendations adopted by each program was 7 (mean 6.3, range 0-9). The most commonly adopted new recommendations were universal mask use by patients in both inpatient and outpatient settings (85% and 87%, respectively) and contact precautions for CF patients in inpatient and outpatient settings (90% for both). The least frequently adopted new recommendations were the “6-foot rule” in inpatient settings (n = 66, 53%) and auditing disinfection of surfaces in clinic (n = 64, 49%). Larger program size was associated with a higher weighted adoption score (odds ratio [OR] 1.9, P =.02).
Conclusions |
Whereas most programs adopted more than one-half of the selected IP&C recommendations assessed, adoption was variable. Efforts to improve adoption of IP&C recommendations should focus on smaller programs with fewer resources.
Le texte complet de cet article est disponible en PDF.Key Words : Infection control
Plan
| Previous presentation: Presented, in part, at the North American Cystic Fibrosis Conference, Indianapolis, IN, November 2017. |
|
| Funding support: Supported by the US Cystic Fibrosis Foundation (grant Nos. SAIM15A0 and STOUDE16B0). |
|
| Conflicts of interests: None to report. |
|
| Author contributions: M.S.M. and L.S. contributed equally to this work. |
Vol 47 - N° 9
P. 1090-1095 - septembre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
